Get the Stockscreener App
3.21
3.31%
-0.11
After Hours:
3.20
-0.010
-0.31%
Larimar Therapeutics Inc stock is traded at $3.21, with a volume of 480.38K.
It is down -3.31% in the last 24 hours and up +17.15% over the past month.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
See More
Previous Close:
$3.32
Open:
$3.34
24h Volume:
480.38K
Relative Volume:
0.39
Market Cap:
$205.53M
Revenue:
-
Net Income/Loss:
$-36.95M
P/E Ratio:
-3.8214
EPS:
-0.84
Net Cash Flow:
$-33.46M
1W Performance:
-5.03%
1M Performance:
+17.15%
6M Performance:
-3.89%
1Y Performance:
-65.59%
1-Day Range:
$3.14
$3.365
1-Week Range:
$3.105
$3.6799
52-Week Range:
$1.61
$9.97
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Name
Larimar Therapeutics Inc
Sector
Industry
Phone
844-511-9056
Address
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
3.21 | 216.41M | 0 | -36.95M | -33.46M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-25 | Initiated | Truist | Buy |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Oct-03-24 | Initiated | Wedbush | Outperform |
| Oct-02-24 | Initiated | H.C. Wainwright | Buy |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Apr-03-24 | Initiated | Leerink Partners | Outperform |
| Nov-17-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-19-22 | Initiated | Guggenheim | Buy |
| Feb-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-10-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-01-21 | Initiated | William Blair | Outperform |
View All
Larimar Therapeutics Inc Stock (LRMR) Latest News
What analysts say about Larimar Therapeutics Inc. stockExponential wealth increase - Autocar Professional
Larimar Therapeutics Inc. Stock Analysis and ForecastRobust investment performance - Jammu Links News
Is Larimar Therapeutics Inc. a good long term investmentSuperior stock selection - Jammu Links News
What drives Larimar Therapeutics Inc. stock priceAccelerated profit realization - Jammu Links News
Is Larimar Therapeutics Inc. stock overhyped or has real potentialHigh Potential Shares - Newser
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - Yahoo Finance
What makes Larimar Therapeutics Inc. stock price move sharplyFree Stock Selection - Newser
Why Larimar Therapeutics Inc. stock attracts strong analyst attentionAI Powered Stock Call - Newser
Larimar Therapeutics Advances Friedreich’s Ataxia Program with New Publications on Nomlabofusp Data - MSN
Larimar Nears Data Readout For Nomlabofusp In Rare Inherited Disorder - RTTNews
Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia - MarketScreener
Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia | LRMR Stock News - GuruFocus
Larimar Therapeutics Publishes Nonclinical Findings Supporting Nomlabofusp's Accelerated Approval Pathway for Friedreich’s Ataxia Treatment - Nasdaq
Larimar Therapeutics Publishes Nonclinical Data Supporting - GlobeNewswire
First Disease-Modifying Treatment for Friedreich's Ataxia Advances Toward FDA Accelerated Approval - Stock Titan
Larimar Therapeutics, Inc.(NasdaqGM: LRMR) added to Russell 3000 Value Index - MarketScreener
Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MSN
Larimar Therapeutics Aligns with FDA Guidance, Revises Nomlabofusp Submission Timeline - MSN
Larimar Therapeutics’ (LRMR) Buy Rating Reaffirmed at Guggenheim - Defense World
Guggenheim Reiterates Buy Rating on Larimar Therapeutics (LRMR) - GuruFocus
Larimar Therapeutics (LRMR) Sees Buying Opportunity After Share Decline | LRMR Stock News - GuruFocus
Analyst Lowers Price Target for Larimar Therapeutics (LRMR) | LR - GuruFocus
Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program | LRMR Stock News - GuruFocus
Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia - The Manila Times
Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia - Yahoo Finance
Millennium Management LLC Acquires Additional Shares in Larimar Therapeutics Inc - GuruFocus
Head-To-Head Survey: Larimar Therapeutics (NASDAQ:LRMR) vs. Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World
ProShare Advisors LLC Makes New $71,000 Investment in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Northern Trust Corp Acquires 14,185 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Larimar Therapeutics, Inc.’s (LRMR): Analysts See 957% Upside Potential - MSN
Larimar Therapeutics’ SWOT analysis: nomlabofusp’s potential lifts FA stock By Investing.com - Investing.com South Africa
Larimar Therapeutics’ SWOT analysis: nomlabofusp’s potential lifts FA stock - Investing.com
Traws Pharma Highlights Q1 2025 Financial Progress and Antiviral Developments - MyChesCo
Larimar Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
Why Did Larimar Therapeutics Soar 10.14% on Q1 Earnings? - AInvest
LRMRLarimar Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Larimar Therapeutics Advances Nomlabofusp Amid Financial Loss - TipRanks
Larimar Therapeutics Inc (NASDAQ: LRMR): Can A Stock Be -26.10% Lower Year-To-Date And Still Be A Loser? - Marketing Sentinel
The time has not yet come to remove your chips from the table: Larimar Therapeutics Inc (LRMR) - Sete News
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Humana (HUM) and Larimar Therapeutics (LRMR) - The Globe and Mail
Stock Traders Buy High Volume of Call Options on Larimar Therapeutics (NASDAQ:LRMR) - Defense World
Larimar Therapeutics Inc Stock (LRMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.59%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):